May 27 (Reuters) - Ironwood Pharmaceuticals Inc:
* IRONWOOD AND ABBVIE REPORT TOP-LINE PHASE II DATA FOR MD-7246 IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D)
* IRONWOOD PHARMACEUTICALS INC - TRIAL DID NOT ACHIEVE STATISTICALLY SIGNIFICANT IMPROVEMENTS IN ABDOMINAL PAIN RELATIVE TO PLACEBO
* IRONWOOD PHARMACEUTICALS INC - COMPANIES PLAN TO DISCONTINUE DEVELOPMENT OF MD-7246
* IRONWOOD PHARMACEUTICALS INC - MD-7246 WAS GENERALLY WELL-TOLERATED IN PHASE II TRIAL IN IBS-D Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.